{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:23:42Z","timestamp":1792805022148,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172669"],"award-info":[{"award-number":["82172669"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sci-Tech Project Foundation of Guangzhou","award":["202102080059"],"award-info":[{"award-number":["202102080059"]}]},{"name":"Guangdong Esophageal Cancer Institute Science and Technology Program","award":["M202117"],"award-info":[{"award-number":["M202117"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To investigate the association between absolute lymphocyte count (ALC) nadir and survival outcomes in esophageal squamous cell carcinoma (ESCC) patients who received definitive chemoradiotherapy (CRT) combined with anti-PD-1 immunotherapy, as well as to explore clinical characteristics and dosimetric parameters that affect ALC nadir during CRT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patients with ESCC (n = 602) who underwent definitive CRT were analyzed, of whom 166 received combined anti-PD-1 immunotherapy and CRT. Changes in ALC and survival were compared between patients with and without immunotherapy. Propensity score matching (PSM) was performed to minimize the effects of confounding factors. Low ALC was defined as nadir of &amp;lt;0.33 \u00d7 103 cells\/\u03bcL during CRT (top tertile). Univariate and multivariate logistic regression were used to identify predictors of low ALC nadir.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients with immunotherapy had significantly higher ALC in the first 3 weeks during CRT and higher ALC nadir than those without. Overall survival was more favorable in patients with immunotherapy both before and after PSM. After a median follow-up of 12.1 months, patients with low ALC during CRT had a worse progression-free survival (PFS) (P = .026). In multivariate analysis, low ALC remained a significant prognostic factor for PFS. Planning target volume (PTV) and heart V5 were revealed to be independent predictors of low ALC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The addition of anti-PD-1 immunotherapy to definitive CRT could mitigate the decline of ALC during radiotherapy and might prolong survival. Low ALC nadir was correlated to worse PFS, larger PTV, and higher heart V5 in patients receiving combined immunotherapy and CRT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad094","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T07:20:29Z","timestamp":1681629629000},"page":"e606-e616","source":"Crossref","is-referenced-by-count":20,"title":["Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy"],"prefix":"10.1093","volume":"28","author":[{"given":"Xingyuan","family":"Cheng","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South People\u2019s Republic of China Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute , Guangzhou , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center , Guangzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqing","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South People\u2019s Republic of China Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute , Guangzhou , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center , Guangzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifen","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South People\u2019s Republic of China Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute , Guangzhou , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center , Guangzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South People\u2019s Republic of China Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute , Guangzhou , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center , Guangzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhan","family":"Zhu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South People\u2019s Republic of China Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute , Guangzhou , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center , Guangzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhong","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South People\u2019s Republic of China Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute , Guangzhou , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center , Guangzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiliang","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South People\u2019s Republic of China Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute , Guangzhou , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center , Guangzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-0970","authenticated-orcid":false,"given":"Mian","family":"Xi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South People\u2019s Republic of China Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute , Guangzhou , People\u2019s Republic of China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center , Guangzhou , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"issue":"2","key":"2023080322071608700_CIT0001","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"suppl 5","key":"2023080322071608700_CIT0002","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"issue":"35","key":"2023080322071608700_CIT0003","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"2023080322071608700_CIT0004","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10302","key":"2023080322071608700_CIT0005","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"2023080322071608700_CIT0006","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"2023080322071608700_CIT0007","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/2326-6066.CIR-14-0069","article-title":"Combining radiation and immunotherapy: a new systemic therapy for solid tumors","volume":"2","author":"Tang","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2023080322071608700_CIT0008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","article-title":"Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination","volume":"6","author":"Gong","year":"2018","journal-title":"J ImmunoTher Cancer"},{"issue":"7","key":"2023080322071608700_CIT0009","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/onco.13797","article-title":"Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma","volume":"26","author":"Zhang","year":"2021","journal-title":"Oncologist"},{"key":"2023080322071608700_CIT0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"issue":"13","key":"2023080322071608700_CIT0011","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"2023080322071608700_CIT0012","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s12094-020-02345-3","article-title":"Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients","volume":"22","author":"Holub","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"2023080322071608700_CIT0013","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy","volume":"99","author":"Davuluri","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2023080322071608700_CIT0014","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.radonc.2018.02.025","article-title":"High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer","volume":"128","author":"Fang","year":"2018","journal-title":"Radiother Oncol"},{"issue":"10","key":"2023080322071608700_CIT0015","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2023080322071608700_CIT0016","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.adro.2020.03.021","article-title":"Lymphopenia and radiation dose to circulating lymphocytes with neoadjuvant chemoradiation in esophageal squamous cell carcinoma","volume":"5","author":"So","year":"2020","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"2023080322071608700_CIT0017","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1002\/onco.13533","article-title":"Lymphopenia during definitive chemoradiotherapy in esophageal squamous cell carcinoma: association with dosimetric parameters and patient outcomes","volume":"26","author":"Xu","year":"2021","journal-title":"Oncologist"},{"issue":"9","key":"2023080322071608700_CIT0018","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1245\/s10434-019-07334-7","article-title":"Treatment-related lymphopenia predicts pathologic complete response and recurrence in esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy","volume":"26","author":"Li","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2023080322071608700_CIT0019","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40425-018-0395-x","article-title":"Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas","volume":"6","author":"Ho","year":"2018","journal-title":"J ImmunoTher Cancer"},{"issue":"5","key":"2023080322071608700_CIT0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","article-title":"Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer","volume":"105","author":"Cho","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2023080322071608700_CIT0021","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"8","key":"2023080322071608700_CIT0022","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"2023080322071608700_CIT0023","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"2023080322071608700_CIT0024","doi-asserted-by":"crossref","first-page":"1758835920926822","DOI":"10.1177\/1758835920926822","article-title":"A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy","volume":"12","author":"Wang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"2023080322071608700_CIT0025","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/annonc\/mdv173","article-title":"ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients","volume":"26","author":"Tredan","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"2023080322071608700_CIT0026","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood-2015-05-645077","article-title":"Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia","volume":"127","author":"Sheikh","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023080322071608700_CIT0027","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16","key":"2023080322071608700_CIT0028","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/cid\/ciaa630","article-title":"Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T Cells","volume":"71","author":"Liu","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2023080322071608700_CIT0029","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","article-title":"T cell regeneration after immunological injury","volume":"21","author":"Velardi","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2023080322071608700_CIT0030","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1567-5769(03)00060-2","article-title":"Immunodeficiency and cancer: prospects for correction","volume":"3","author":"Hadden","year":"2003","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2023080322071608700_CIT0031","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-015-1841-y","article-title":"Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas","volume":"124","author":"Campian","year":"2015","journal-title":"J Neurooncol"},{"issue":"31","key":"2023080322071608700_CIT0032","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.2217\/fon-2021-0632","article-title":"RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma","volume":"17","author":"Yu","year":"2021","journal-title":"Future Oncol"},{"issue":"10","key":"2023080322071608700_CIT0033","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2217\/fon-2020-0969","article-title":"KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma","volume":"17","author":"Shah","year":"2021","journal-title":"Future Oncol"},{"issue":"11","key":"2023080322071608700_CIT0034","first-page":"2148","article-title":"Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"128","author":"Park","year":"2022","journal-title":"Cancer-Am Cancer Soc"},{"issue":"4","key":"2023080322071608700_CIT0035","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2023080322071608700_CIT0036","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/e606\/51034751\/oyad094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/e606\/51034751\/oyad094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:08:16Z","timestamp":1691100496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/e606\/7123816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4,15]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad094","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,4,15]]}}}